Chromogranin A ELISA is for Research Use Only.
Eagle Biosciences’ Chromogranin A ELISA in our Cancer Biomarker Assay Kit Line. The Cancer Biomarker Assay Kit Line offered Eagle Biosciences provides a comprehensive array of sensitive and valuable tools to assist researchers in new emerging market segments in cancer research such as tumor marker and antitumor therapy investigation.
Our Chromogranin A ELISA is one of the unique assays in the this Cancer Biomarker Assay Kit Line that offers excellent sensitivity, precise results in under 3 hours, and exclusive measurement of human chromogranin A without the high dose “hook” effect up to 1,000,000 ng/ml.
Why Measure Chromogranin A?
Chromogranin A (CgA) is a 49 kDa acidic protein that consists of 439 amino acids encoded on chromosome 14. It has been identified in a number of normal and neoplastic endocrine tissues. In fact, chromogranin A is a highly sensitive and specific marker for pheochromocytoma, carcinoids, and other neuroendocrine tumors (NET) . Molina et. al describes “CgA is one of the most used tumor markers in NETs, and elevated CgA concentrations have been demonstrated in serum or plasma of patients with different types of these tumors .”
The measurement of Chromogranin A provides incredible value to scientists studying numerous areas of cancer research beyond other biomarkers utilized for the detection, evaluation, and monitoring of specific tumor types.
Key Advantages of EagleBio’s Chromogranin ELISA, CHR31-K01
- Excellent Sensitivity
- Precise results under 3 hours
- Measures CgA without the high dose “hook” effect up to 1,000,000 ng/ml.
- Competitive Price
Recent Citations for EagleBio’s Chromogranin A ELISA
Molina et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumor Biol. (2011) 32:13–2. PMID:20730520
2. Molina et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumor Biol. (2011) 32:13–2. PMID:20730520